Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aerovate Therapeutics Inc (AVTE)

Aerovate Therapeutics Inc (AVTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,626
  • Shares Outstanding, K 28,822
  • Annual Sales, $ 0 K
  • Annual Income, $ -75,520 K
  • 60-Month Beta 1.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.56
Trade AVTE with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 47.82%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 408.44% on 06/04/24
  • IV Low 0.00% on 08/30/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 41
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 3,314
  • Open Int (30-Day) 4,419

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.59
  • Number of Estimates 2
  • High Estimate -0.56
  • Low Estimate -0.62
  • Prior Year -0.71
  • Growth Rate Est. (year over year) +16.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6100 +19.88%
on 08/06/24
1.9600 -1.53%
on 08/26/24
+0.1100 (+6.04%)
since 07/30/24
3-Month
1.2500 +54.40%
on 06/20/24
25.2850 -92.37%
on 06/14/24
-15.7300 (-89.07%)
since 05/30/24
52-Week
1.2500 +54.40%
on 06/20/24
32.4150 -94.05%
on 04/01/24
-14.0500 (-87.92%)
since 08/29/23

Most Recent Stories

More News
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the...

AVTE : 1.9300 (+4.32%)
Aerovate Therapeutics Announces First Quarter 2022 Financial Results

WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on...

AVTE : 1.9300 (+4.32%)
Aerovate Therapeutics Announces Full-Year 2021 Financial Results

Initiated IMPAHCT, a global Phase 2b/Phase 3 trial of AV-101 for pulmonary arterial hypertension (PAH) in December 2021Received FDA guidance in April 2021...

AVTE : 1.9300 (+4.32%)
Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

WALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on...

AVTE : 1.9300 (+4.32%)
Aerovate Therapeutics Announces Third Quarter 2021 Financial Results

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on...

AVTE : 1.9300 (+4.32%)
Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

WALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc.  (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...

AVTE : 1.9300 (+4.32%)
Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

WALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc.    (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...

AVTE : 1.9300 (+4.32%)
Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors

BOSTON, July 19, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients...

AVTE : 1.9300 (+4.32%)
Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

BOSTON, July 02, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients...

AVTE : 1.9300 (+4.32%)
Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients...

AVTE : 1.9300 (+4.32%)

Business Summary

Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 2.0833
2nd Resistance Point 2.0067
1st Resistance Point 1.9683
Last Price 1.9300
1st Support Level 1.8533
2nd Support Level 1.7767
3rd Support Level 1.7383

See More

52-Week High 32.4150
Fibonacci 61.8% 20.5100
Fibonacci 50% 16.8325
Fibonacci 38.2% 13.1550
Last Price 1.9300
52-Week Low 1.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar